Protara Therapeutics (TARA) Depreciation & Amortization (CF) (2013 - 2026)
Protara Therapeutics (TARA) recorded quarterly Depreciation & Amortization (CF) of $90000.0 in Q1 2026, down 3.23% quarter-over-quarter from $93000.0 in Q4 2025, and up 8.43% on a YoY basis from $83000.0 in Q1 2025.
Protara Therapeutics (TARA) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Protara Therapeutics' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $90000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 8.43% year-over-year to $90000.0; the TTM figure through Mar 2026 stood at $369000.0 (up 11.14% YoY), while the FY2025 annual figure was $362000.0, up 9.04% from the prior year.
- Depreciation & Amortization (CF) was $90000.0 for Q1 2026 at Protara Therapeutics, down from $93000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $107000.0 in Q4 2023 to a low of $53000.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $80764.7 across 5 years, with a median of $83000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 366.67% in 2022, then slipped 23.36% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $75000.0 in 2022, then jumped by 42.67% to $107000.0 in 2023, then retreated by 23.36% to $82000.0 in 2024, then grew by 13.41% to $93000.0 in 2025, then declined by 3.23% to $90000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $90000.0 (Q1 2026), $93000.0 (Q4 2025), and $88000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Protara Therapeutics | 216.35 Mn | 216.35 Mn | - | 90,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90,000.00 |
| Mar 31, 2026 | 90,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 82,000.00 |
| Dec 31, 2024 | 82,000.00 |
| Sep 30, 2024 | 84,000.00 |
| Sep 30, 2024 | 84,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Dec 31, 2023 | 107,000.00 |